BNET Industries
Market Cap:$142.0M
Last Fiscal Year Sales:$18.4M
- Public
- US
Dow Jones Description
We believe that how we collaborate on the discovery and development of important medical innovations is essential to our overall success. We recognize all creative endeavors whether creating new drugs or making great music depend on an inspirational spark that always originates with the individual. But we also understand that sustainable innovation can only flourish in a community that supports and appreciates the inspired action of each individual.
Chair and Chief Executive OfficerSteven H. Holtzman
Number of Employees 161
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Market Maker Surveillance Report. Top 6 Losing Stocks With Lowest Price Friction For April 15,...
-
AZ Chief appointed head of PhRMA
News & Analysis
Filter by
infinity pharmaceuticals inc. - All News and Analysis
Biotechnology Winners Show Investors Big Potential.
By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Nov. 10--In the hot area of biotechnology investment, the chief recipients of venture capital in the third quarter would seem at first to have little in common. For instance,...
Additional Resources
2009 Results Announced: Best Places to Work in Industry
The Scientist, magazine of the lifesciences, announced today the winners of its 7th annual Best Places to Work inIndustry survey. This year's survey yielded responses fromrepresentatives of 238 life sciences companies worldwide. InfinityPharmaceuticals in Cambridge, Massachusetts, took top honors and led thetrend of small company dominance in...
Infinity's choices
John Keilty has been promoted to vice president of information technology and informatics at Infinity Pharmaceuticals Inc. He is a member of the company's executive leadership team. Infinity has also named Joseph McPherson vice president of facilities and operations...
Infinity Pharmaceuticals Inc
But Infinity Pharmaceuticals Inc. Nasdaq plummeted $2.41, or 29%, to $5.83 after the company called an early halt to a late-stage clinical trial of a drug intended to treat tumors of the digestive tract. The company said it stopped a trial of IPI-504 as a treatment for gastrointestinal stromal tumors....
Zacks Analyst Blog Highlights: Infinity Pharmaceuticals Inc, Novartis, Pfizer, OmniVision Technologies Inc and Google
http://www.profits.zacks.com/ CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity...
Global alliance
Purdue Pharma LP has entered into an international alliance with Infinity Pharmaceuticals Inc. The goal is to advance discovery and development programs in neuropathic pain and oncology...
Hydra Biosciences Bolsters Discovery and IP Capabilities with Key Additions to Executive Management Team
CAMBRIDGE, Mass. -- Hydra Biosciences, a privately held biopharmaceutical company focused on developing novel drugs using its expertise in Transient Receptor Potential TRP ion channels, announced today the expansion of its executive management team with the appointments of David Kimball, Ph.D. as Chief Scientific Officer and Christine Bellon, Ph.D. as...
Wall Street Media Presents Exclusive Videos from the Baird Small-Cap Healthcare Conference
NEW YORK -- Wall Street Media presents exclusive video of Steven B. Porter, M.D, Ph. D., Chief Medical Officer of Intermune, Inc., (NASDAQ: ITMN), discussing their partnership with Roche. http://www.wsmco.com/show.aspx?1077_Now's_the_time_for_ small-cap_stocks And we're pleased to feature video of Dr. Steven H. Holtzman, Chairman, President and Chief...
The Scientist Announced Today the Results of Its 6th Annual Best Places to Work in Industry Survey
The Scientist, magazine of the lifesciences, announced today the winners of its 6th annual Best Places to Work in Industrysurvey . This year's survey yielded responses from representatives of207 life sciencescompanies worldwide . Smaller companies consistently ranked higheroverall. Family-run Tec Laboratories in Albany, Oregon, took the top...
Gaithersburg-based MedImmune announces name for protein inhibitor
Infinity Pharmaceuticals Inc. (Nasdaq:INFI) and MedImmune Inc. today announced that the United States Adopted Names USAN Council, in consultation with the World Health Organization WHO International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary or generic name "retaspimycin" for the companies' lead heat shock protein 90 (Hsp90)...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Adelene Q. Perkins | President & Chief Business Officer |
| Julian Adams | President & Chief Scientific Officer |
| David S. Grayzel | Vice President, Clinical Dev & Medical Affairs |
| Gerald E. Quirk | General Counsel & Vice President |
| James L Wright | Vice President, Pharmaceutical Dev |
| Jeffrey K Tong | Vice President, Corp & Product Dev |
| John J Keilty | Vice President, Information Technology and Informatics |
| Michael S Curtis | Vice President, Pharmaceutical Development |
| Steven J. Kafka | Vice President |
| Vito J. Palombella | Vice President, Drug Discovery |
| Dr Frank Moss | Co-Founder |
| Eric S Lander | Co-Founder |
| Roxanne Duan | Founder |
| Arnold J. Levine | Lead Research & Development Director |
| Christian C Fritz | Senior Director, Cancer Biology |
| Christine P. Bellon | Director, Intellectual Property & Senior Patent Counsel |
| Jeanette W Kohlbrenner | Senior Director, Human Resources |
| Margaret A. Read | Senior Director, Cancer Biology |
| Christopher M Lindblom | Principal Accounting Officer |
| Harry F. Hixson | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Steven H. Holtzman | Chair and Chief Executive Officer |
| Vicki L. Sato | Lead Outside Director and Chair of Infinity's Compensation Committee |
| Anthony B. Evnin | Board of Directors |
| Ian F. Smith | Chair |
| Michael C. Venuti | Chair of Infinity's Research and Development Committee |
| D. Ronald Daniel | Board of Directors |
| Franklin H. Moss | Board of Directors |
| Herm Rosenman | Board of Directors |
| James Tananbaum | Board of Directors |
| Martin Babler | Board of Directors |
| Patrick Lee | Board of Directors |
Steven H. Holtzman , age 55, has served as our Chief Executive Officer and Chair of our board of directors since September 2006, and as our president from October 2007 to October 2008. Mr. Holtzman is also a co-founder of Old Infinity and served as its Chief Executive Officer and as Chair of its board of directors from inception in 2001 through completion of the reverse merger. Mr. Holtzman has also served as President of Old Infinity from July 2001 to February 2006. From 1994 to 2001, Mr. Holtzman served as Chief Business Officer of Millennium Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. From 1996 to 2001, Mr. Holtzman served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. Prior to joining Millennium Pharmaceuticals, Inc., from 1986 to 1994, Mr. Holtzman was a founder and Executive Vice President of DNX Corporation, a publicly-traded biotechnology company. Mr. Holtzman is a director of Anadys Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and a trustee of the Berklee College of Music. Mr. Holtzman received a B.A. in Philosophy from Michigan State University and a B.Phil. in Philosophy from Oxford University, which he attended as a Rhodes Scholar.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Chair and Chief Executive Officer | Current |
| Corpus Christi College | Chief | Current |
| University of Oxford | Chief | Current |
| The Convergence Forum | Founder | Current |
| Berklee College of Music | Trustee | Current |
| Nantucket Conference | Current | |
| Life Sciences, Inc. | Board of Directors | Current |
| Anadys Pharmaceuticals, Inc. | Board of Directors | Current |
| Archemix Corp | Board of Directors | Current |
| Berklee College of Music | Board of Directors | Current |
| Millennium Pharmaceuticals, Inc. | Chief Business Officer | Former |
| DNX Corporation | Executive Vice President | Former |
| DNX Corporation | Founder | Former |
| Infinity Pharmaceuticals, Inc | Founder | Former |
| Corpus Christi College | Instructor | Former |
| Infinity Pharmaceuticals, Inc | Executive Officer | Former |
| Millennium Pharmaceuticals, Inc. | Leader | Former |
| Rigid Building Systems Ltd. | Former | |
| Biotechnology Industry Organization | Chairman | Former |
| University of Oxford | Graduate Degree In Philosophy | Former |
| Michigan State University | B.A. In Philosophy | Former |
Adelene Q. Perkins is President and Chief Business Officer. Ms. Perkins joined Infinity in June of 2002 and brings over 20 years of general management experience in the healthcare, pharmaceutical, and biotechnology industries. At Infinity her leadership responsibilities include product and corporate development, business development, finance, legal, commercial, organization development and human resources, IR/PR, and facilities and operations. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as Vice President of Business and Corporate Development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Wyeth, where she was Vice President of Emerging Businesses and the cofounder and General Manager of the DiscoverEase™ Business Unit. She also formed and served as Chief Executive Officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University directed at discovering and developing members of the TGF-b superfamily. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives and was responsible for numerous business development transactions, including both in- and out-licensing technologies and products. From 1985-1992, Ms. Perkins was at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry. Ms. Perkins holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from Villanova University. She is on the Board of Project Hope and the Villanova University College of Engineering Advisory Board.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | President & Chief Business Officer | Current |
| West Membership Co | Chief Business Officer, Infinity Pharmaceuticals | Current |
| Project Hope | Vice Chair | Current |
| Project Hope | Board of Directors | Current |
| Metamorphix, Inc. | Chief Executive Officer | Former |
| Infinity Pharmaceuticals, Inc | Executive Vice President and Chief Business Officer | Former |
| West Membership Co | Vice President of Business | Former |
| Infinity Pharmaceuticals, Inc | Principal Financial Officer | Former |
| Genetics Institute, Inc. | Former | |
| Villanova University | B.S. In Chemical Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | President & Chief Scientific Officer | Current |
| Auspex Pharmaceuticals Privacy Policy | Board of Directors | Current |
| Proscript | Executive Vice President of R&D | Former |
| Millennium Pharmaceuticals, Inc. | Senior Vice President, Drug Discovery and Development | Former |
| LeukoSite, Inc. | Senior Vice President of R&D | Former |
| Boehringer Ingelheim Corporation | Former | |
| Rigid Building Systems Ltd. | Former | |
| Predix Pharmaceuticals Holdings, Inc. | Board of Directors | Former |
| Massachusetts Institute of Technology | Ph.D. | Former |
| McGill University | B.S. | Former |
David S. Grayzel, M.D., is Vice President, Clinical Development and Medical Affairs. Dr. Grayzel is currently responsible for leading Infinity's clinical research efforts and oversees both clinical development and clinical operations. Prior to Infinity, he was at Dyax Corp., a biopharmaceutical company focused on antibody and protein therapeutics. At Dyax, he was Director of Corporate Development and Business Operations, responsible for marketing and commercialization strategy for therapeutic products in the development pipeline, including late-stage clinical trials as well as business initiatives for in-licensing of targets, out-licensing of late-stage compounds, and co-development partnerships. Dr. Grayzel obtained his medical degree at Harvard Medical School and completed his internship and residency training in Internal Medicine at Massachusetts General Hospital. Prior to his medical training, Dr. Grayzel was a Curriculum Director at Stanford University Medical Center, creating their first case-based medical ethics curriculum. He holds a B.A. with honors from Stanford University.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Vice President, Clinical Dev & Medical Affairs | Current |
| Dyax Corp. | Director of Corporate Development | Former |
| Stanford University Medical Center | Curriculum Director | Former |
| Massachusetts General Hospital | Residency | Former |
| Stanford University | B.A. With Honors | Former |
| Harvard Medical School | Degree | Former |
Gerald E. Quirk, Esq., is Vice President and General Counsel. He is responsible for Infinity’s legal and compliance initiatives, as well as the company’s intellectual property portfolio. He has extensive experience representing biotechnology companies in connection with securities offerings and SEC compliance activities, mergers and acquisitions, licensing and other collaboration agreements, and product commercialization initiatives. Prior to joining Infinity, Mr. Quirk served in a number of progressively responsible legal and business development positions at Genzyme Corporation, having most recently been responsible for the provision of all non-patent legal services to Genzyme’s oncology, cardiovascular, and medical device businesses. Mr. Quirk began his career as an associate in the business law department and biotechnology practice group at Palmer & Dodge LLP, a Boston law firm. Mr. Quirk earned his J.D. from Northeastern University School of Law, an Ed.M. in Educational Administration from Harvard University, and a B.A. in Political Science from Swarthmore College.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | General Counsel & Vice President | Current |
| Palmer Dodge Inc. | Associate | Former |
| Genzyme Corporation | Former | |
| Northeastern University School of Law | J.D. | Former |
| Swarthmore College | B.A. In Political Science | Former |
| Harvard University | Educational Administration | Former |
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Vice President, Pharmaceutical Dev | Current |
Jeffrey K. Tong, Ph.D., is Vice President, Corporate and Product Development. Dr. Tong is responsible for leading Infinity's product development teams and corporate development efforts. Prior to joining Infinity, Dr. Tong was with the Palo Alto office of McKinsey & Company, where his work focused in healthcare with projects for leading biotechnology and pharmaceutical companies in areas of new business building, technology spinouts, and venture investing. Prior to McKinsey, Dr. Tong was a founding researcher of the Harvard Center for Genomics Research. Dr. Tong received his educational training at the interface of molecular biology, synthetic chemistry, and medicine. His previous research interest was in the area of histone deacetylase biology where he was involved with multiple teams in the identification and functional characterization of novel histone deacetylases and their macromolecular complexes. Dr. Tong holds A.B. and M.M.S. degrees from Harvard College and Harvard Medical School, respectively, as well as A.M. and Ph.D. degrees from Harvard University under the direction of Professor Stuart Schreiber.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Vice President, Corp & Product Dev | Current |
| Harvard College | M.S. Degrees | Former |
| Harvard Medical School | M.S. Degrees | Former |
| Harvard University | A.B. | Former |
| Harvard Medical School | A.B. | Former |
| Harvard College | A.B. | Former |
| Harvard Medical School | Degree | Former |
| Harvard College | Degree | Former |
John J. Keilty is Vice President, Information Technology and Informatics. Mr. Keilty is responsible for information systems, software development, structural biology, bioinformatics, and clinical informatics. Prior to joining Infinity, Mr. Keilty was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, including Senior Manager of Molecular Research Services with broad ownership for the creation, management, implementation and transfer of much of the company’s core genomic technologies. Many of the developed software applications, algorithms and laboratory procedures were transferred to Millennium’s corporate partners as part of larger business collaborations. Before Millennium, Mr. Keilty worked in the Howard Hughes lab of Michael Green at University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing. Mr. Keilty holds a B.A. in biology from Clark University.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Vice President, Information Technology and Informatics | Current |
| Infinity Pharmaceuticals, Inc | Senior Director | Former |
| Millennium Pharmaceuticals, Inc. | Board of Directors | Former |
| Clark University | B.A. In Biology | Former |
Michael S. Curtis, Ph.D., is Vice President of Pharmaceutical Development with responsibility for manufacturing, formulation, and analytical characterization of Infinity's pre-clinical and clinical drug candidates. Prior to joining Infinity, Dr. Curtis was an Associate Director within the Pharmaceutical and Analytical Development group at Transkayotic Therapies (TKT, currently Shire) where he was responsible for analytical methods development and validation to support the registration of Elaprase® (idursulfase). Before TKT, Dr. Curtis was the Associate Director of Analytical Development at Syntonix Pharmaceuticals where he was involved with advancing the Transceptor® drug delivery technology and in particular its expansion as an oral delivery platform. Prior to Syntonix, he was a member of the Therapeutic Protein Research group at Genzyme working on the development and characterization of the enzyme replacement therapy Myozyme® (alglucosidase alfa). Dr. Curtis began his career at Bristol-Myers Squibb where he held positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril) and Taxol® (paclitaxel) and the early development of Orencia® (abatacept). Dr. Curtis received his B.S. in Biochemistry from the State University of New York College of Environmental Science and Forestry and his Ph.D. in Cell and Molecular Biology from Upstate Medical University.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Vice President, Pharmaceutical Development | Current |
| Syntonix Pharmaceuticals, Inc. | Associate Director of Analytical Development | Former |
| Bristol-Myers Squibb Company | Former | |
| Upstate Medical University | Ph.D. In Cell and Molecular Biology | Former |
Steven J. Kafka, Ph.D., is Vice President, Finance. Dr. Kafka oversees investor and public relations, financial planning and analysis, accounting, treasury, purchasing, and business operations. Dr. Kafka joined Infinity from Millennium Pharmaceuticals, where he was Senior Director, Finance. As leader of the Financial Planning and Analysis group at Millennium, he and his team were responsible for corporate business planning, financial management, and product portfolio strategy support. He also served as a member of the VELCADE® leadership team where he helped to establish and guide the product’s U.S. commercial strategy and operations and its global co-development strategy with partner Johnson & Johnson. Dr. Kafka worked for several years as a senior member of the life sciences practice of Strategic Decisions Group (SDG), a business strategy consulting firm, where he specialized in the pharmaceutical industry. His experience at SDG included leadership of portfolio integration efforts for the merger of two global pharmaceutical firms, establishment of portfolio strategy and ongoing management for the Japanese assets of a global biopharmaceutical firm, and product development strategy projects across a host of therapeutic areas.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Vice President | Current |
| Millennium Pharmaceuticals, Inc. | Senior Director | Former |
| Johnson & Johnson | Member | Former |
| Rigid Building Systems Ltd. | Former | |
| Sdg Corporation | Former |
Vito J. Palombella, Ph.D., is Vice President, Drug Discovery. Prior to joining Infinity, Dr. Palombella was at Syntonix Pharmaceuticals. At Syntonix he was Director of Molecular Biology and Protein Chemistry, responsible for improving and expanding its core Fc receptor-mediated drug delivery technology. Before joining Syntonix, Dr. Palombella was Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, which he joined through its acquisition of LeukoSite (where he held the same title) in 1999. Prior to its acquisition by LeukoSite, Dr. Palombella held a number of positions at ProScript, Inc. (between 1994 and 1999). While at ProScript, LeukoSite, and Millennium, Dr. Palombella was involved in the discovery and development of VELCADE®, a proteasome inhibitor for cancer therapy. He also managed a number of additional projects, including research into NF-?B regulation. Dr. Palombella received a B.S. in Microbiology from Rutgers University and his M.S. and Ph.D. in Viral Oncology and Immunology from the New York University Medical Center. He was also a post-doctoral fellow at Harvard University in the laboratory of Dr. Tom Maniatis.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Vice President, Drug Discovery | Current |
| Millennium Pharmaceuticals, Inc. | Senior Director of Cell and Molecular Biology | Former |
| Syntonix, Inc | Director of Molecular Biology | Former |
| Harvard University | Fellow | Former |
| Proscript | Former | |
| LeukoSite, Inc. | Former | |
| Syntonix Pharmaceuticals, Inc. | Former | |
| New York University Medical Center | Ph.D. In Viral Oncology and Immunology | Former |
| New York University Medical Center | M.S. | Former |
| Rutgers University | B.S. In Microbiology | Former |
Frank Moss, Ph.D., is a co-founder of Infinity. Since 1998, Dr. Moss has been President of Strategic Software Ventures, a firm that nurtures enterprise software startup companies; since February 2006, Dr. Moss has served as Director of The Media Lab and Weisner Professor of Media Arts and Sciences at the Massachusetts Institute of Technology. From 1991 - 1996, Dr. Moss served as Chief Executive Officer and Chairman of Tivoli Systems, a private software company sold to IBM in 1996. Prior to joining Tivoli Systems, Dr. Moss held a variety of positions with Lotus Development, Stellar Computer, Apollo Computer, and IBM Research. Dr. Moss received a B.S. in Aerospace and Mechanical Sciences from Princeton University and an S.M. and Ph.D. in Aeronautics and Astronautics from the Massachusetts Institute of Technology.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Co-Founder | Current |
| Nantucket Conference | Current | |
| Cylant, Inc. | Current | |
| The Convergence Forum | Board of Directors | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| The Advisory Council | Board of Directors | Current |
| The Convergence Guide | Board of Directors | Current |
| Tivoli Systems | CEO | Former |
| Systinet Corporation | co-founder | Former |
| Onaro, Inc. | Former | |
| Computer Reseller News | Former | |
| Bowstreet, Inc. | Former | |
| Lotus Development Corporation | Former | |
| International Business Machines Corporation | Former | |
| Tivoli Systems | later chairman | Former |
| Massachusetts Institute of Technology | doctorate in Aeronautics and Astronautics | Former |
| Princeton University | B.S. in Aerospace and Mechanical Sciences | Former |
Eric S. Lander, Ph.D., is a co-founder of Infinity. Dr. Lander has been a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology since 1990 and a Professor of Systems Biology at Harvard Medical School since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993 - 2003, Dr. Lander was the Director of the Whitehead/MIT Center for Genome Research. Dr. Lander received an A.B. in Mathematics from Princeton University and a D.Phil. in Mathematics from Oxford University, which he attended as a Rhodes Scholar.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Co-Founder | Current |
| Access Excellence | Associate Professor of Biology and Director of the Center for Genome Research | Current |
| Harvard Medical School | Professor of Systems Biology | Current |
| The Sacred Balance | Current | |
| Backup-Reports.Com | Current | |
| Entertainment Industry Foundation | Board of Directors | Current |
| Broad Medical Research Program | Board of Directors | Current |
| Millennium Pharmaceuticals, Inc. | Board of Directors | Current |
| Genetics Society of America | Board of Directors | Current |
| Whitehead Institute for Biomedical Research | Board of Directors | Current |
| National Academy of Sciences | Board of Directors | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| National Academy of Sciences | Member | Current |
| Genetics Society of America | Member | Current |
| Sciences, Inc | Board of Directors | Former |
| University of Oxford | Ph.D. In Mathematics | Former |
| Princeton University | B.A. In Mathematics | Former |
| Sciences, Inc | Member | Former |
| Whitehead Institute for Biomedical Research | Member | Former |
| Organization | Position | Status |
|---|---|---|
| National Cancer Institute | Former | |
| Women In Bio Co | Board of Directors | Current |
| The University of California, San Francisco | Ph.D. Degree | Former |
Arnold J. Levine, Ph.D., is a Professor at The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine and a Professor at the Institute for Advanced Study. From 1998 - 2002, Dr. Levine was President of Rockefeller University. Prior to joining Rockefeller University, Dr. Levine was the Harry C. Weiss Professor in the Life Sciences and Chairman of the Department of Molecular Biology at Princeton University from 1984 - 1996. Dr. Levine also serves as a Director of Theravance, Inc. and Applera Corporation, publicly traded life science companies. Dr. Levine received a B.A. in Biology from Harpur College, State University of New York at Binghamton and a Ph.D. in Microbiology from the University of Pennsylvania.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Lead Research & Development Director | Current |
| Cancer Institute | Prof | Current |
| Institute for Advanced Studies | Visiting Professor | Current |
| The Cancer Institute of New Jersey | Professor | Current |
| Celera Diagnostics, LLC | Current | |
| Celera Genomics | Current | |
| Bg Medicine, Inc. | Co-Chairman | Current |
| Theravance, Inc. | Chairperson | Current |
| Applied Biosystems Group | Board of Directors | Current |
| Exsar Corporation | Board of Directors | Current |
| National Academy of Sciences | Board of Directors | Current |
| Avidimer Therapeutics, Inc. | Board of Directors | Current |
| Theravance, Inc. | Board of Directors | Current |
| The Ellison Medical Foundation | Board of Directors | Current |
| Functional Genetics, Inc. | Board of Directors | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| Applera Corporation | Director | Current |
| Theravance, Inc. | Committee Member | Current |
| The Rockefeller University | Chief Executive Officer | Former |
| The Rockefeller University | President | Former |
| Princeton University | Professor | Former |
| The Rockefeller University | Visiting Professor | Former |
| Princeton University | Chairman | Former |
| University of Pennsylvania | Ph.D. In Microbiology | Former |
| University of Pennsylvania School of Medicine | PhD In Microbiology | Former |
| State University of New York at Binghamton | B.A. | Former |
| National Academy of Sciences | member | Former |
| United States Public Health Services (USPHS) | Fellow | Former |
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Senior Director, Cancer Biology | Current |
| Millennium Pharmaceuticals, Inc. | Senior Scientist | Former |
| University of Cologne | Doctor of Philosophy, Genetics, Molecular Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Director, Intellectual Property & Senior Patent Counsel | Current |
Jeanette W. Kohlbrenner is Senior Director, Human Resources. She is responsible for Infinity’s human resource and organizational development functions. Ms. Kohlbrenner joined Infinity with over 15 years of experience in senior human resource roles with life science and medical device companies, ranging from start-up to fully commercial, global organizations. Prior to joining Infinity, Ms. Kohlbrenner was the Business Unit Director of Human Resources for Cambrex Biosciences, with responsibilities for pharmaceutical development and manufacturing locations in the United States. Before Cambrex, Ms. Kohlbrenner was at Syntonix Pharmaceuticals, where she was the Director of Human Resources and a key member of the senior team, working to build the company. Ms. Kohlbrenner also held human resource roles with Genetics Institute/Wyeth Pharmaceuticals, and Hewlett-Packard’s Medical Device business (now Philips Medical). Early in her career, Ms. Kohlbrenner was a compensation and performance management consultant with William Mercer, a global leader in human resource consulting. Ms. Kohlbrenner holds an M.B.A. from Babson College and a B.A. in Mathematics from Holy Cross.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Senior Director, Human Resources | Current |
| Syntonix Pharmaceuticals, Inc. | Former | |
| Babson College | M.B.A. | Former |
| Holy Cross | B.A. In Mathematics | Former |
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Senior Director, Cancer Biology | Current |
| Harvard Medical School | Instructor | Former |
| Proscript | Former | |
| Millennium Pharmaceuticals, Inc. | Director | Former |
| Vanderbilt University | Ph.D. | Former |
| The University of Tennessee | B.S. In Biology, Continuing on To | Former |
| Vanderbilt University | Postdoctoral, Molecular Microbiology | Former |
Vicki L. Sato, Ph.D., Lead Outside Director and Chair of Infinity's Compensation Committee, is currently a professor at Harvard University. From 1992 - 2005, Dr. Sato held various positions with Vertex Pharmaceuticals, Inc., a publicly traded pharmaceutical company, most recently serving as President from 2000 - 2005. Prior to joining Vertex Pharmaceuticals, Inc., from 1984 - 1992, Dr. Sato held various positions with Biogen, Inc., a publicly traded biotechnology company, most recently serving as Vice President of Research and a member of the Scientific Advisory Board. Since 1993, Dr. Sato has served on the Board of Tutors, Department of Biochemistry and Molecular Biology at Harvard University, and also served as an Assistant Professor and Associate Professor in the Department of Biology at Harvard University from 1975 - 1983. Dr. Sato is a business advisor to Atlas Ventures, a venture capital firm, and other enterprises in the biotechnology and pharmaceutical industries. Dr. Sato serves as an overseer of the Isabella Stewart Gardner Museum and is a trustee of Jose Mateo’s Ballet Theatre. Dr. Sato serves as a director of Bristol-Myers Squibb Company and Alnylam Pharmaceuticals, Inc., publicly traded biopharmaceutical companies, Perkin-Elmer, Inc., a diversified company with businesses in the life and analytical sciences and optoelectronics, and Avila Therapeutics, a private biotechnology company. Dr. Sato received an A.B. in Biology from Radcliffe College and an M.A. and Ph.D. in Biology from Harvard University.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Lead Outside Director and Chair of Infinity's Compensation Committee | Current |
| Bristol-Myers Squibb Company | Professor of Management Practice at the Harvard Business School and Professor | Current |
| Harvard Business School | Professor of Management Practice | Current |
| Alnylam Pharmaceuticals, Inc. | Professor of Management Practice | Current |
| Harvard University | Professor of Molecular and Cell Biology | Current |
| Vertex, Inc. | Current | |
| Alnylam Pharmaceuticals, Inc. | Chair | Current |
| Ballet Theatre | Board of Directors | Current |
| Alnylam Pharmaceuticals, Inc. | Board of Directors | Current |
| Bioventures Investors | Board of Directors | Current |
| Tutors LLC | Board of Directors | Current |
| Bristol-Myers Squibb Company | Board of Directors | Current |
| Vertex Pharmaceuticals Incorporated | President | Former |
| Biogen, Inc. | Former | |
| Harvard University | M.A. | Former |
| Radcliffe College | A.B. In Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Principal Accounting Officer | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
Anthony B. Evnin, Ph.D. , a director since October 2006, is a General Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He is currently a member of the Board of Directors of Icagen, Inc., Infinity Pharmaceuticals, Inc and Sunesis Pharmaceuticals, Inc., as well as being on the Board of Directors of a number of private companies. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
| Organization | Position | Status |
|---|---|---|
| Venrock Associates | Managing General Partner | Current |
| Pharmos Corporation | Managing General Partner, Venrock Associates | Current |
| Renovis, Inc. | Board of Directors | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| Vela Pharmaceuticals, Inc. | Current | |
| Infinity Pharmaceuticals, Inc | Chair of Infinity's Nominating and Governance Committee | Current |
| Venrock Associates | Board of Directors | Current |
| Acceleron Pharma Inc | Board of Directors | Current |
| The Rockefeller University | Board of Directors | Current |
| Uv Partners | Board of Directors | Current |
| Coley Pharmaceutical Group Inc. | Board of Directors | Current |
| Icagen, Inc. | Board of Directors | Current |
| Alta Partners | Director | Current |
| Memory Pharmaceuticals Corp. | Board of Directors | Current |
| Pharmos Corporation | Director | Current |
| Altea Therapeutics | Board Member | Current |
| Metabolex, Inc. | Board Member | Current |
| Aveo Pharmaceuticals, Inc. | Board of Directors | Current |
| Cancer Immunity | Board of Directors | Current |
| Triangle Pharmaceuticals, Inc. | Board of Directors | Current |
| Celladon | Director | Current |
| Caliper Technologies | Board of Directors | Current |
| Syntonix Pharmaceuticals, Inc. | Director | Current |
| Sonic Innovations, Inc. | Board of Directors | Current |
| Union Carbide Corporation | Research Scientist | Former |
| Gilead Sciences, Inc. | Former | |
| Sunesis Pharmaceuticals, Inc. | Board of Directors | Former |
| IDEXX Laboratories, Inc. | Investor | Former |
| Sepracor Inc. | Investor | Former |
| Triangle Pharmaceuticals, Inc. | Investor | Former |
| Sonic Innovations, Inc. | Investor | Former |
| Centocor, Inc. | Investor | Former |
| Caliper Life Sciences, Inc. | Investor | Former |
| IDEC Pharmaceuticals | Investor | Former |
| Massachusetts Institute of Technology | Ph.D. in chemistry | Former |
| Massachusetts, Inc. | Ph.D. In Chemistry | Former |
| Princeton University | A.B. | Former |
| Memory Pharmaceuticals Corp. | member | Former |
Ian Smith joined Vertex in November 2001. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. As Vertex’s CFO, Mr. Smith holds responsibility for a wide variety of core functions at Vertex, including Finance, Strategic Communications, Information Systems and Operations. Mr. Smith is also a member of the Executive Team at Vertex. Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University. Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute. Mr. Smith is a member of the Board of Directors of Acorda Therapeutics, Inc, Epix Pharmaceuticals, Inc. and TolerRx Inc. Additionally, he is a board member of the Massachusetts Biotechnology Council and is Chair of its Policy Committee.
| Organization | Position | Status |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | Executive Vice President and Chief Financial Officer | Current |
| Vertex, Inc. | Executive Vice President | Current |
| Infinity Pharmaceuticals, Inc | Chair | Current |
| Acorda Therapeutics, Inc. | Board of Directors | Current |
| TolerRx, Inc. | Board of Directors | Current |
| Predix Pharmaceuticals Holdings, Inc. | Board of Directors | Current |
| Vertex Pharmaceuticals Incorporated | Board of Directors | Current |
| Prohost Biotechnology | Board of Directors | Current |
| American Institute of Certified Public Accountants | Member | Current |
| Vertex, Inc. | Chief Financial Officer | Former |
| Vertex Pharmaceuticals Incorporated | Senior Vice President | Former |
| Vertex, Inc. | Senior Vice President | Former |
| Vertex, Inc. | Vice President | Former |
| Life Science!, Inc | Partner | Former |
| Ernst & Young | partner | Former |
| Manchester Metropolitan University | B.A. with honors in accounting | Former |
Array
| Organization | Position | Status |
|---|---|---|
| University of California, San Francisco | Adjunct Professor of Chemistry | Current |
| Global Health Limited | Executive Scientific Advisor | Current |
| University of California | Adjunct Prof of Chemistry | Current |
| Infinity Pharmaceuticals, Inc | Chair of Infinity's Research and Development Committee | Current |
| Discovery Partners International, Inc. | Board of Directors | Current |
| Discovery Partners International, Inc. | Chief Executive Officer | Former |
| Infinity Pharmaceuticals, Inc | Acting Chief Executive Officer | Former |
| Axys Pharmaceuticals | Chief Technical Officer | Former |
| Infinity Pharmaceuticals, Inc | Chief Scientific Officer | Former |
| Axys Pharmaceuticals | Senior Vice President, Research and Preclinical Development | Former |
| Axys Pharmaceuticals | General Manager | Former |
| Axys Pharmaceuticals | Director of Medicinal Chemistry | Former |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
Array
| Organization | Position | Status |
|---|---|---|
| Sequenom, Inc. | Chairman of the Board of Directors | Current |
| Infinity Pharmaceuticals, Inc | Director | Current |
| San Diego Opera | Member of the Board | Current |
| Discovery Partners International, Inc. | Board of Directors | Current |
| Signal Pharmaceuticals, LLC | Director | Current |
| Arena Pharmaceuticals, Inc. | Director | Current |
| Arena Pharmaceuticals, Inc. | Member | Current |
| Braincells, Inc. | Chief Executive Officer | Former |
| Amgen Inc. | President and Chief Operating Officer and Member | Former |
| Braincells, Inc. | Co-Founder | Former |
| Abbott Laboratories | Former | |
| Discovery Partners International, Inc. | Chairman | Former |
| Sequenom, Inc. | Board of Directors | Former |
| University of Chicago | M.B.A. | Former |
| Purdue University | B.S. In Chemical Engineering | Former |
| Amgen Inc. | Member | Former |
| Organization | Position | Status |
|---|---|---|
| Gen-Probe Inc. | Senior Vice President, Finance and Chief Financial Officer | Current |
| ARYx Therapeutics Inc | Board of Directors | Current |
| Discovery Partners International, Inc. | Board of Directors | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| Radnet Management Inc. | Chief Executive Officer | Former |
| Radnet Management Inc. | President | Former |
| PricewaterhouseCoopers | partner | Former |
| Cooper's Inc. | Partner | Former |
| Wharton Graduate School of the University of Pennsylvania | M.B.A. In Finance | Former |
| Wharton Graduate School of the University of Pennsylvania | B.B.A. In Finance | Former |
| Pace University | B.B.A. In Finance | Former |
| Organization | Position | Status |
|---|---|---|
| Novavax, Inc. | Managing Director, Prospect Venture Partners | Current |
| Amira Pharmaceuticals Inc | Managing Director and Co-Founder of Prospect Venture Partners II and III | Current |
| Prospect Venture Partners | Managing Director | Current |
| Vitae Pharmaceuticals, Inc | Co-Founder | Current |
| Golden Gate Chapter | Officer | Current |
| Young Presidents' Organization | Officer | Current |
| Novavax, Inc. | Director | Current |
| Cornerstone Therapeutics, Inc. | Director | Current |
| Young Presidents' Organization | Board of Directors | Current |
| Bird Flu Guardian | Board of Directors | Current |
| Vanda Pharmaceuticals Inc. | Director | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| Vitae Pharmaceuticals, Inc | Board of Directors | Current |
| Roxro Pharma, Inc | Board of Directors | Current |
| Amira Pharmaceuticals Inc | Board of Directors | Current |
| Young Presidents' Organization | Member | Current |
| GelTex Pharmaceuticals | Acting CEO | Former |
| Infinity Pharmaceuticals, Inc | Acting CEO | Former |
| Theravance, Inc. | Chief Executive Officer | Former |
| Geltex, LLC | Founder | Former |
| Infinity Pharmaceuticals, Inc | Founder | Former |
| GelTex Pharmaceuticals | Co-Founder | Former |
| Prospect Venture Partners | Co-Founder | Former |
| Theravance, Inc. | Founder | Former |
| Prospect Venture Partners | Managing Partner | Former |
| Sierra Ventures | Partner | Former |
| Infinity Pharmaceuticals, Inc | Manager | Former |
| Merck & Co. Inc. | senior product manager | Former |
| Amerigroup Corporation | Investor | Former |
| Healtheon | Investor | Former |
| Harvard University | MD | Former |
| Harvard Medical School | M.D. | Former |
| Harvard University | MBA | Former |
| Yale University | Undergraduate Degree | Former |
| Harvard University | Undergraduate Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Talima | President and Chief Executive Officer | Current |
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
Patrick Lee is a General Partner of Ares Life Sciences, an investment firm, since February 2009. Prior to Ares Life Sciences, Mr. Lee was a General Partner at Advent Venture Partners, a venture capital firm, where he was employed since 1999. Before Advent Venture Partners, from 1989 - 1999, Mr. Lee held various positions with Rhone-Poulenc Rorer in the U.S., and Rhone-Poulenc in Paris, France, where he was most recently Group Vice President for Mergers and Acquisitions. Prior to that he had been with Baxter International and Booz Allen Hamilton. Mr. Lee received a B.A. in Biology from Vassar College and an M.B.A. from the Stanford Graduate School of Business.
| Organization | Position | Status |
|---|---|---|
| Infinity Pharmaceuticals, Inc | Board of Directors | Current |
| Conatus Pharmaceuticals Inc | Board of Directors | Current |
| Speciality European Pharma Limited | Board of Directors | Current |
| RhOne-Poulenc | Group Vice President for Mergers & Acquisitions | Former |
| Advent Venture Partners Llp. | General Partner | Former |
| Rhone-Poulenc Rorer | Former | |
| Advent Inc. | Former | |
| Booz Allen Hamilton, Inc. | Former | |
| Stanford Graduate School of Business | M.B.A. | Former |
| Vassar College | B.A. In Biology | Former |
Executive News
-
BioSeek renews deal with Merck Serono
-
BioSeek renews deal with Merck Serono
-
BioSeek and Merck Serono Extend 2008 Agreement
-
BioSeek renews deal with Merck Serono
-
Janet Wolfe of Wolfe Laboratories Inc. Honored at 2009 WEST Leadership Awards Celebration
-
Janet Wolfe Honored at 2009 WEST Leadership Awards Celebration
-
New Paper in Science Features Infinity's IPI-926 Hedgehog Pathway Inhibitor as a...
-
Infinity Pharmaceuticals Named Winner of The Scientist's 'Best Places to Work in...
-
Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
-
Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
Industry Transcripts by Seeking Alpha
-
BMP Sunstone Corporation Q1 2009 Earnings Call Transcript
on Jun 30, 2009about BJGP
-
Matrixx Initiatives, Inc., F4Q09 (Qtr End 03/31/09) Earnings Call Transcript
on May 12, 2009about MTXX
-
King Pharmaceuticals Inc., Q1 2009 Earnings Call Transcript
on May 11, 2009about KG
-
Flamel Technologies SA Q1 2009 Earnings Call Transcript
on May 11, 2009about FLML
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
on May 08, 2009about SCMP
Glass Door
IndustryTop Rated
- AstraZeneca's Seroquel Research Director Confessed to Sex-for-Studies Affairs 17 votes
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds 11 votes
- Medarex Execs Got 10% Pay Raise Despite Delivering Nothing 11 votes
- Pfizer District Sales Manager Guilty of Altering Off-Label Celebrex Documents 10 votes
- Gilead Whistleblower Suit: A Bullet Dodged 10 votes
